The Effects of D-Fagomine on Glycaemic Response to Sucrose in Men

Randomized Controlled Double-blind Nutritional Intervention Trial to Evaluate the Effects of D-fagomine on Glycaemic Response to Sucrose in Men

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01528631

Enrollment

Registered

2012-02-08

Start date

2012-02-29

Completion date

2012-06-30

Last updated

2012-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glycaemic Response, Insulinemic Response

Brief summary

The aim of this study is to evaluate the effect of D-fagomine on glycaemic response to sucrose in men.

Detailed description

To determine and compare glycaemic response to sucrose of D-Fagomine and control in the timeframe of 180 minutes.

Interventions

OTHERD-Fagomine

30 mg (initial dose), with 50 grams of sucrose in 200 ml of water.

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

MALE

Age

20 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

1\. Males between the ages of 20 and 70 willing and able to provide written informed consent.

Exclusion criteria

1. LDL cholesterol levels higher than 189 mg/dl 2. Triglycerides higher than 350 mg/dl (the threshold level to determine c-LDL using the Friedewald formula) 3. Physical examinations and routine biochemical analysis shall be conducted to rule out pathologies. 4. Consumption of supplements or acetylsalicylic acid 5. Chronic alcoholism 6. Body mass index (BMI) greater than 30 kg/m2 7. Previous antihypertensive treatment at the start of the trial that has not finished at least 2 months before beginning the study 8. Diabetes mellitus (if the fasting blood glucose is higher than 126 mg/dl, the test should be repeated and confirmed) 9. Kidney disease (serum creatine levels above 1,4 mg/dl for women and above 1,5 mg/dl for men) 10. Acute infectious diseases, malignant tumors, severe liver failure, respiratory failure associated with chronic or endocrine diseases 11. Other conditions such as special dietary needs 12. To be participating or having participated in a clinical trial within the last 3 months 13. Inability to continue the study 14. History of gastrointestinal disease which may alter the absorption of nutrients 15. Depressive disorder or thoughts of self-injury

Design outcomes

Primary

Measure	Time frame
Glycaemic response to sucrose	0-180 minutes

Secondary

Measure	Time frame
Insulin in venous plasma	0-180 minutes

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026